Table 3. Univariate and Multivariate analyses for risk factors associated with 30-day mortality in patients with MRSA bacteremia.

	Univariate analysis			Multivariate analysis
Risk Factor	No.(%) of patients		p-value	HR	95% CI		p-value
	Survival(n = 209)	Death(n = 98)			Lower	Upper
Agea	58.6±16.0	63.1±14.1	0.017b
Acquisition
Hospital-onset	178 (85)	81 (83)	0.572
Health care-acquired	203 (97)	93 (95)	0.327
Underlying diseases
Diabetes	63 (30)	34 (35)	0.424
Cancer	24 (12)	21 (21)	0.022b	2.026	1.228	3.343	0.006b
Liver cirrhosis	19 (9)	10 (10)	0.756
Renal replacement therapy	20 (10)	8 (8)	0.690
Congestive heart failure	18 (9)	12 (12)	0.324
Cerebrovascular accident	44 (21)	21 (21)	0.940
Chronic obstructive lung disease	7 (3)	11 (11)	0.006b
Primary site of infection
Skin and soft tissue	46 (22)	19 (19)	0.600
Bone and joint	19 (9)	7 (7)	0.568
Lung	16 (8)	13 (13)	0.117
Intravascular catheter-related	74 (35)	27 (28)	0.172
Intra-abdominal infection	18 (0)	5 (5)	0.276
Primary bacteremia	38 (18)	27 (28)	0.061
Complicated bacteremia
Infective endocarditis	1 (0)	1 (1)	0.537
Other metastatic infection	9 (4)	8 (8)	0.168
Persistent bacteremia	16 (8)	12 (12)	0.193
APACHE II scorea	16.5±6.9	27.0±9.3	<0.001b	1.127	1.102	1.152	<0.001b
Treatment
Adequate antibiotics within 48 hours	81 (39)	36 (37)	0.734
Glycopeptides as definitive antibiotics	163 (78)	68 (69)	0.104
Eradication of infection foci	95 (46)	22 (22)	<0.001b	0.575	0.349	0.950	0.031b
Microbiological characteristics
SCCmec IV/IVa MRSA	38 (18)	20 (20)	0.642
hetero-VISA	13 (6)	6 (6)	0.974
agr dysfunction	72 (34)	36 (37)	0.696
Vancomycin MIC = 2 µg/mL	27 (13)	12 (12)	0.869

NOTE. HR, hazard ratio; CI, confidence interval; APACHE, acute physiology and chronic health evaluation; SCCmec IV/IVa MRSA, MRSA possessing SCCmec type IV or IVa; hetero-VISA, hetero-vancomycin-intermediate S. aureus; MIC, minimum inhibitory concentration.

^aContinuous variables are expressed as means (±SD).

^bStatistically significant (P≤0.05).